For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | - | - |
| Research and development | 11,634 | 13,143 | 13,120 | 12,528 |
| General and administrative | 4,092 | 4,399 | 4,871 | 4,596 |
| Total operating expenses | 15,726 | 17,542 | 17,991 | 17,124 |
| Operating loss | -15,726 | -17,542 | -17,991 | -17,124 |
| Interest income | 697 | 850 | 997 | 1,598 |
| Interest expense | 1,341 | 1,301 | 1,263 | 1,244 |
| Loss on extinguishment of debt | 0 | 0 | - | - |
| Other income, net | 0 | 11 | 168 | 97 |
| Total other (expense) income | -644 | -440 | -98 | 451 |
| Net loss | -16,370 | -17,982 | -18,089 | -16,673 |
| Basic EPS | -0.36 | -0.4 | -0.4 | -0.38 |
| Diluted EPS | -0.36 | -0.4 | -0.4 | -0.38 |
| Basic Average Shares | 45,804,042 | 44,981,746 | 44,827,159 | 43,704,836 |
| Diluted Average Shares | 45,804,042 | 44,981,746 | 44,827,159 | 43,704,836 |
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)